This notice provides information to 340B covered entities regarding how to acquire Adempas® (riociguat) tablets at the 340B ceiling price.

Adempas® (riociguat) tablets NDC: 50419-0250-01, 50419-0250-03, 50419-0250-91, 50419-0251-01, 50419-0251-03, 50419-0251-91, 50419-0252-01, 50419-0252-03, 50419-0252-91, 50419-0253-01, 50419-0253-03, 50419-0253-91, 50419-0254-01, 50419-0254-03, 50419-0254-91

Adempas® is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with:

- Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1)
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)

Adempas® has a Risk Evaluation and Mitigation Strategy (REMS) Program associated with it and therefore has a restricted distribution system. To take possession of the drug, a pharmacy must become REMS certified.

Adempas® is available to patients in the following ways:

(1) Individual patient prescriptions for Adempas® may be filled by the following network specialty pharmacies: CVS Specialty Pharmacy (1-877-242-2738) or Accredo Specialty Pharmacy (1-866-344-4874);

(2) 340B covered entities that use Accredo Specialty Pharmacy as their contracted pharmacy may purchase Adempas at the 340B ceiling price thru Accredo. 340B covered entities not contracted with Accredo can contract with Accredo Contracted 340B Specialty Pharmacy to fulfill their patient prescriptions. Accredo Contracted 340B Specialty Pharmacy can be contacted at (615) 943-7500 or gene.mccabe@accredo.com and sales_info@accredo.com.

Additional information on this Limited Distribution system for Adempas may be found at Adempas.com or call 1-888-84Bayer for further assistance.